1. Home
  2. ERAS vs GTN Comparison

ERAS vs GTN Comparison

Compare ERAS & GTN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ERAS
  • GTN
  • Stock Information
  • Founded
  • ERAS 2018
  • GTN 1897
  • Country
  • ERAS United States
  • GTN United States
  • Employees
  • ERAS N/A
  • GTN N/A
  • Industry
  • ERAS Biotechnology: Pharmaceutical Preparations
  • GTN Broadcasting
  • Sector
  • ERAS Health Care
  • GTN Industrials
  • Exchange
  • ERAS Nasdaq
  • GTN Nasdaq
  • Market Cap
  • ERAS 432.6M
  • GTN 491.0M
  • IPO Year
  • ERAS 2021
  • GTN N/A
  • Fundamental
  • Price
  • ERAS $1.37
  • GTN $4.32
  • Analyst Decision
  • ERAS Strong Buy
  • GTN Strong Buy
  • Analyst Count
  • ERAS 6
  • GTN 3
  • Target Price
  • ERAS $4.83
  • GTN $6.33
  • AVG Volume (30 Days)
  • ERAS 1.8M
  • GTN 1.9M
  • Earning Date
  • ERAS 03-20-2025
  • GTN 05-06-2025
  • Dividend Yield
  • ERAS N/A
  • GTN 7.42%
  • EPS Growth
  • ERAS N/A
  • GTN N/A
  • EPS
  • ERAS N/A
  • GTN 3.36
  • Revenue
  • ERAS N/A
  • GTN $3,644,000,000.00
  • Revenue This Year
  • ERAS N/A
  • GTN N/A
  • Revenue Next Year
  • ERAS N/A
  • GTN $14.86
  • P/E Ratio
  • ERAS N/A
  • GTN $1.28
  • Revenue Growth
  • ERAS N/A
  • GTN 11.06
  • 52 Week Low
  • ERAS $1.23
  • GTN $2.91
  • 52 Week High
  • ERAS $3.45
  • GTN $7.41
  • Technical
  • Relative Strength Index (RSI)
  • ERAS 39.36
  • GTN 49.61
  • Support Level
  • ERAS $1.40
  • GTN $3.40
  • Resistance Level
  • ERAS $1.61
  • GTN $5.29
  • Average True Range (ATR)
  • ERAS 0.11
  • GTN 0.28
  • MACD
  • ERAS 0.01
  • GTN -0.05
  • Stochastic Oscillator
  • ERAS 4.00
  • GTN 31.21

About ERAS Erasca Inc.

Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.

About GTN Gray Television Inc.

Gray Media Inc is a multimedia company. The company owns and operates local television stations and digital assets. It also owns Gray Digital Media, a full-service digital agency offering national and local clients digital marketing strategies with digital products and services. Its additional media properties include video production companies Raycom Sports, Tupelo Media Group, and PowerNation Studios, and studio production facilities Assembly Atlanta and Third Rail Studios.

Share on Social Networks: